This website is intended for Healthcare Professionals. If you are not a Healthcare Professional please click here
Prescribing
Information

Frequently Asked Questions

  • The patient may have been prescribed a refill cartridge and this should be used together with the inhaler. Each inhaler can be used with up to 6 refill cartridges
  • Not to throw the Respimat® re-usable inhaler away when the cartridge is empty.
  • The cartridge should be replaced when the indicator changes colour to red with a white arrow indicating that the cartridge is empty.
  • To get a new prescription when the dose counter changes colour to yellow

Respimat® re-usable is available as a single pack (one Respimat® re-usable inhaler plus one cartridge) and a single refill pack (one cartridge). One cartridge contains 60 puffs (30 medicinal doses).

Each re-usable inhaler may be used with up to six cartridges, after which time a new Respimat® re-usable inhaler pack should be prescribed.
There is an option within prescribing systems which allows a prescriber to choose refills.

Yes. When designing the Respimat® re-usable, only a few secondary components of the Respimat® inhaler, such as the dose indicator and the length of the body, had to be modified or added. Delivered dose (DD) and particle size distribution (PSD) of the Respimat® re-usable inhaler were compared with data from a disposable Respimat®. Performance, in terms of delivered dose and fine particle dose, was unchanged. The delivered doses over nine cartridges were also stable and consistently within the upper and lower limits of the reference inhaler.

No. The Respimat® re-usable inhaler is licenced for use with up to six cartridges.

Boehringer Ingelheim simplified handling, improved readability of the dose indicator and redesigned the Respimat® for re-use with multiple cartridges based on patient and physician feedback. The Respimat® re-usable also offers the potential to reduce environmental impact from re-use with up to six cartridges.

Although the basic handling steps (i.e., cartridge insertion, priming and daily use) for Respimat® re-usable are very similar to those of the disposable Respimat®, some handling aspects of Respimat® re-usable are not the same. Therefore, Boehringer Ingelheim have demonstrated adequate handling of Respimat® re-usable in three usability studies. In a study involving 16 participants with previous experience of the Respimat® inhaler, the majority of patients favored the Respimat® re-usable. The cartridge exchange feature and each handling step was rated in favour of the Respimat® re-usable.

The Respimat® re-usable inhaler is labelled with a cartridge counter to help patients keep track of how many cartridges they have used. One box on the label should be ticked each time a new cartridge is inserted, and the inhaler should be replaced after the sixth cartridge has been used.

The dose indicator shows how many puffs remain in the cartridge. When there are 10 puffs (5 medicinal doses) remaining the indicator will change from white to yellow and a patient should obtain a new cartridge. When the cartridge indicator turns red the cartridge is used up.

The Respimat® re-usable inhaler will not lock after use with six cartridges.

No. Respimat® re-usable should be cleaned in the same way as the disposable Respimat®. The recommended cleaning period and cleaning instructions (i.e., clean the mouthpiece at least once per week with a damp cloth) remain unchanged.

Yes. As the Respimat® re-usable inhaler simply replaced the previous, disposable Respimat® inhaler, the product licence numbers were unchanged.

The Respimat® re-usable was available from 17th of September 2019, after which time the previous disposable Respimat® was no longer available for prescription.

PC-GB-100908 V1 - October 2020
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (Freephone) or PV_local_uk_ireland@boehringer-ingelheim.com
The information on this website has been created by Boehringer Ingelheim. For product information, including patient leaflets and summary of product characteristics, please see Product Information section.
PC-GB-100901 V1 - October 2020